Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-27
2005-12-27
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253010, C514S254050, C544S124000, C544S364000, C546S206000, C546S256000
Reexamination Certificate
active
06979686
ABSTRACT:
A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R1, R2, R3and R4are as described in the specification.
REFERENCES:
patent: 3254093 (1966-05-01), Huisgen et al.
patent: 3984431 (1976-10-01), Gueremy et al.
patent: 4000281 (1976-12-01), Beiler et al.
patent: 5051518 (1991-09-01), Murray et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5486534 (1996-01-01), Lee et al.
patent: 5559137 (1996-09-01), Adams et al.
patent: 5589439 (1996-12-01), Goto et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5739143 (1998-04-01), Adams et al.
patent: 5756529 (1998-05-01), Isakson et al.
patent: 5972972 (1999-10-01), Mihelich et al.
patent: 5998425 (1999-12-01), Adams et al.
patent: 6423713 (2002-07-01), Anantanarayan et al.
patent: 6514977 (2003-02-01), Anantanarayan et al.
patent: 6525059 (2003-02-01), Anantanarayan et al.
patent: 6617324 (2003-09-01), Naraian et al.
patent: 295 374 (1991-10-01), None
patent: 0 115 640 (1983-12-01), None
patent: 0 418 845 (1991-03-01), None
patent: 0 515 041 (1992-11-01), None
patent: 0 531 901 (1993-03-01), None
patent: 0 846 686 (1998-06-01), None
patent: 0 846 687 (1998-06-01), None
patent: 4-145081 (1992-05-01), None
patent: 5-17470 (1993-01-01), None
patent: 5-345772 (1993-12-01), None
patent: 8-183787 (1996-07-01), None
patent: WO 83/00330 (1983-02-01), None
patent: WO 92/19615 (1992-11-01), None
patent: WO 94/19350 (1994-09-01), None
patent: WO 95/06036 (1995-03-01), None
patent: WO 95/22545 (1995-08-01), None
patent: WO 95/31451 (1995-11-01), None
patent: WO 96/03385 (1996-02-01), None
patent: WO 96/21452 (1996-07-01), None
patent: WO 96/21654 (1996-07-01), None
patent: WO 96/40143 (1996-12-01), None
patent: WO 97/01551 (1997-01-01), None
patent: WO 97/23479 (1997-07-01), None
patent: WO 97/25046 (1997-07-01), None
patent: WO 97/25047 (1997-07-01), None
patent: WO 97/25048 (1997-07-01), None
patent: WO 97/32583 (1997-09-01), None
patent: WO 97/35855 (1997-10-01), None
patent: WO 97/35856 (1997-10-01), None
patent: WO 97/47618 (1997-12-01), None
patent: WO 98/07425 (1998-02-01), None
patent: WO 98/16230 (1998-04-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 98/52937 (1998-11-01), None
patent: WO 98/52937 (1998-11-01), None
patent: WO 98/52940 (1998-11-01), None
patent: WO 98/52941 (1998-11-01), None
patent: WO 98/57968 (1998-12-01), None
patent: WO 99/01130 (1999-01-01), None
patent: WO 99/01131 (1999-01-01), None
patent: WO 99/01136 (1999-01-01), None
patent: WO 99/01452 (1999-01-01), None
patent: WO 99/17776 (1999-04-01), None
patent: WO 99/32121 (1999-07-01), None
patent: WO 99/58523 (1999-11-01), None
patent: WO 99/61426 (1999-12-01), None
patent: WO 00/31072 (2000-06-01), None
Boehm, J.C. et al., “New Inhibitors Of p38 Kinase”, Exp. Opin. Ther. Patents, vol. 10(1), pp. 25-36, (2000).
Laszlo, S.E. et al., “Pyrroles And Other Heterocycles as Inhibitors Of p38 Kinase”,Bioorganic&Medicinal Chemistry Letters 8, pp. 2689-2694, 1998.
Dannhardt G. et al., “t107 -Aminopropyl-pyrazole durch Ringtransformation von Enaminonen der Pyrrolidinreihe”, Arch. Pharm., vol. 321, No. 1, pp. 17-19, 1988.
Zheng-Nian Huang, “Synthesis and Biological Activities of 1-(substituted pyrazol-4-yl)-1,2,4-triazoles”,Chemical Abstracts, vol. 124, No. 23, Abstract No. 317062d, 1996.
Chemical Abstracts, 13thCollective Chemical Substance Index 1992-1996, Book 51, pp. 546-550.
Zhengming, Li et al., “Syntheses of Di-heterocyclic Compounds; Pyrazolylimidazoles And Isoxazolylimadazoles”,Heteroatom, Chem., vol. 9, No. 3, pp. 317-320, 1998.
Zheng-Nian Huang, “The Reaction Of α-OXO-α-Triazolyketene Dithioacetal With Amines, Hydrazine And Cuanidine”, Chinese Chemical Letters, vol. 5, No. 1, pp. 31-34, 1994.
Popova, A.N. et al., “Synthesis Of 4-(Pyrazol-4-yl)-Substituted Salts Of Pyrylium and Pyridines”,Chemical Abstracts, vol. 098, No. 1, Jan. 3, 1983, Abstract No. 004498.
Bauer, V.J. et al., “4-3(5)-Pyrazolyl Pyridinium Salts. A New Class of Hypoglycemic Agents”, J. Med Chem., vol. 11; pp. 981-984, (Sep. 1968).
Cativiela, C. et al., “On the Synthesis of 3(5)-(Carbomethoxy)-4-hetarylprrazoles”, J. Heterocycl. Chem., vol. 25; pp. 851-855, (May-Jun. 1988).
Fischer, U. et al., “1,3-Dipolar Additions To 7-Methylthieno [2,3-c]pyridine 1,1-dioxide”, Helv. Chim. Acta; vol. 63(6), No. 180, pp. 1719-1727, (1980).
Badger, Alison M. et al., “Disease-Modifying Activity Of SB 242235, A Selective Inhibitor Of p38 Mitogen-Activated Protein Kinase, In Rat Adjuvant-Induced Arthritis”,Arthritis&Rheumatism, vol. 43, No. 1, pp. 175-183, 2000.
Henry, James R., “p38 Mitogen-Activated Protein Kinase As A Target For Drug Discovery”,Drugs of the Future, vol. 24, pp. 1345-1354, 1999.
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention Cytokine-Mediated Diseases”, Current Medicinal Chemistry, Issue 6, pp. 807-823, 1999.
Liverton, N.J. et al., “Design And Synthesis Of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors Of p38 Kinase Mitogen-Activated Protein Kinase”,J. Med. Chem., vol. 42, pp. 2180-2190, 1999.
Adams, J.L.. et al., “Pyrimidinylimidazole Inhibitors Of CSBP/p38 Kinase Demonstrating Decreased Inhibition Of Hepatic Cytochrome p450 Enzymes”,Bioorganic&Medicinal Chemistry Letters, vol. 8, pp. 3111-3116, 1998.
Gallagher, T.F., “Regulation Of Stress-Induced Cytokine Production By Pyridlnylimidazoles; Inhibition Of CSBP Kinase”,Bioorganic&Medicinal Chemistry, vol. 5, pp. 49-64, 1997.
Hanson, G.J., “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis”, Exp. Opin. Ther. Patents, vol. 7, pp. 729-733, 1997.
Moerck R.E. et al., “Pyrazole Addition To Δ1-Azirines. Structure of Purported 2:1 Adducts of Δ1-Azirines With sym-Tetrazines”, J.Chem. Soc., Chem. Commun., No. 19, pp. 782-783 (1974).
US. Appl. No. 09/083,670, filed May 22, 1998, Anantanarayan et al, Aug. 3, 1999 Office action and May 16, 2000, notice of allowance for abandoned.
U.S. Patent Appl. No. 10/254,445, filed Sep. 25, 2002, Allen et al, Pending independent claims.
U.S. Patent Appl. No. 10/406,150, filed Mar. 2, 2003, Allen et al, Pending independent claims.
U.S. Patent Appl. No. 10/456,933, filed Jun. 5, 2003, Benson, et al, Pending independent claims.
U.S. Patent Appl. No. 09/512,696, Anatanarayan et al., filed Feb. 24, 2000, Dec. 26, 2000 Office Action and Aug. 13, 2001 Office Action from Abandoned.
Clare Michael
Collins Paul W.
Crich Joyce Zuowu
Devraj Rajesh
Flynn Daniel L.
Harness & Dickey & Pierce P.L.C.
Pharmacia Corporation
Solola Taofiq
LandOfFree
Substituted pyrazoles as p38 kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazoles as p38 kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazoles as p38 kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516522